NEW PUBLICATION

TwinStrand DuplexSeq measuring MRD in AML

AML MRD ASSAY

Are you ready for molecular MRD detection with greater sensitivity?

TwinStrand’s AML MRD assay is the only error-corrected Next-Generation Sequencing (NGS)-based technology that provides ultrasensitive detection with variant identification down to <0.01% limit of detection.

Variant identification down to 1 in 10,000 limit of detection

Sensitive detection of MRD-associated mutations in AML enables accurate response quantification and remission identification. Our AML MRD assay provides significantly greater sensitivity and accuracy for detecting ultra-low frequency mutations than traditionally used methods such as Multiparameter Flow Cytometry (MFC) and standard NGS panels.

Unmatched specificity and analytical sensitivity

Duplex Sequencing technology eliminates background errors for a > 10,000-fold increase in sensitivity over standard NGS

AML MRD assay outperformed MFC to more accurately identify adult reLAPse subjects

Detection of AML-associated mutations at <0.01% VAF

Our AML MRD assay covers key mutations in current testing guidelines

ASXL1 BCOR BRAF CALR CBL CEBPA
CSF3R DDX41 DNMT3A ETV6 EZH2 FLT3
GATA2 IDH1 IDH2 JAK2 KIT KRAS
MPL NPM1 NRAS PHF6 PPM1D PTEN
PTPN11 RAD21 RUNX1 SETBP1 SF3B1 SRSF2
STAG2 TET2 TP53 U2AF1 WT1 ZRSR2

Error-corrected NGS for ultrasensitive MRD detection in AML